Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
This study is currently recruiting participants.
Study NCT00130936.
Last updated on September 22, 2008.
Information provided by Alberta Cancer Board
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
